Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents

European Urology

Volumn 66, Issue 3, 2014, Pages 459-465

  Pezaro, Carmel J ^a   Omlin, Aurelius G ^a   Altavilla, Amelia ^a   Lorente, David ^a   Ferraldeschi, Roberta ^a   Bianchini, Diletta ^a   Dearnaley, David ^a   Parker, Christopher ^a   De Bono, Johann S ^a   Attard, Gerhardt ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; Cabazitaxel; Castration resistant prostate cancer; Enzalutamide; Treatment sequencing

Indexed keywords

ABIRATERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PHENYLTHIOHYDANTOIN; PROSTATE SPECIFIC ANTIGEN; TAXOID;

ANALOGS AND DERIVATIVES; BLOOD; DISEASE COURSE; DISEASE FREE SURVIVAL; HUMAN; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETREATMENT; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT FAILURE;

ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETREATMENT; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT FAILURE;

EID: 84905911748     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.11.044     Document Type: Article

References (20)

1. I.F. Tannock, R. de Wit, and W.R. Berry et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
2. P.W. Kantoff, C.S. Higano, and N.D. Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
3. J.S. De Bono, S. Oudard, and M. Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
4. J.S. De Bono, C.J. Logothetis, and A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
5. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
6. C. Parker, S. Nilsson, and D. Heinrich et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
7. Y. Loriot, D. Bianchini, and E. Ileana et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
8. K.L. Noonan, S. North, R.L. Bitting, A.J. Armstrong, S.L. Ellard, and K.N. Chi Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802 1807
9. A.J. Schrader, M. Boegemann, and C.-H. Ohlmann et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone Eur Urol 65 2014 30 36
10. D. Bianchini, D. Lorente, and A.V. Rodriguez et al. Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone Eur J Cancer 50 2014 78 84
11. M.S. Darshan, M.S. Loftus, and M. Thadani-Mulero et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Cancer Res 71 2011 6019 6029
12. J. Mezynski, C. Pezaro, and D. Bianchini et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23 2012 2943 2947
13. H.I. Scher, S. Halabi, and I. Tannock et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
14. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
15. A.J. Armstrong, E.S. Garrett-Mayer, Y.C. Yang, R. de Wit, I.F. Tannock, and M. Eisenberger A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 2007 6396 6403
16. A.C. Mita, L.J. Denis, and E.K. Rowinsky et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 2009 723 730
17. P. Vrignaud, D. Semiond, and P. Lejeune et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors Clin Cancer Res 19 2013 2973 2983
18. T.A. Yap, C.J. Pezaro, and J.S. de Bono Cabazitaxel in metastatic castration-resistant prostate cancer Expert Rev Anticancer Ther 12 2012 1129 1136
19. A.C. Mita, R. Figlin, and M.M. Mita Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res 18 2012 6574 6579
20. M.L. Zhu, C.M. Horbinski, M. Garzotto, D.Z. Qian, T.M. Beer, and N. Kyprianou Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res 70 2010 7992 8002